Research Analysts Offer Predictions for BCRX Q1 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, February 25th. Wedbush analyst L. Chico anticipates that the biotechnology company will post earnings per share of ($0.06) for the quarter. Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.15 EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.69 EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.09 EPS.

BCRX has been the subject of several other reports. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays lifted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $8.36 on Thursday. The business has a 50 day simple moving average of $8.07 and a 200-day simple moving average of $7.85. The stock has a market capitalization of $1.73 billion, a P/E ratio of -13.70 and a beta of 1.75. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 earnings per share.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $33,000. Venturi Wealth Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $46,000. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Finally, KBC Group NV grew its position in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 4,537 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.